| Previous Close | 0.0400 |
| Open | 0.0400 |
| Bid | 0.0400 x 0 |
| Ask | 0.0450 x 0 |
| Day's Range | 0.0400 - 0.0450 |
| 52 Week Range | 0.0300 - 0.1300 |
| Volume | 84,316 |
| Avg. Volume | 178,701 |
| Market Cap | 5.129M |
| Beta (5Y Monthly) | -12.08 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0180 |
| Earnings Date | Feb. 28, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Lattice Announces Strategic Advisory Board
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice" or the "Company"), an emerging leader in psilocybin research and cannabis company, today announced the formation of its Strategic Advisory Board, a group of respected business leaders that will provide guidance to Lattice’s executive team as it continues to build and strengthen the Company's portfolio of cannabis and psilocybin related brands and products
- Business Wire
Lattice Announces Strategic Cannabis Supply Agreement With Firehouse
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice" or the "Company"), an emerging leader in psilocybin research and cannabis company, today announced it has entered into a Strategic Supply Agreement (the "Agreement") with Firehouse LLC ("Firehouse"), one of Montana’s most established medical cannabis producers.
- Business Wire
Lattice Biologics Reorganizes to Focus on Psychedelics and Cannabis Therapies
Lattice Biologics Ltd. (TSX-V: LBL) (OTCBB: LBLTF) ("Lattice Biologics" or the "Company") announced today that the Company will change its business strategy to focus on the fast growing psychedelics and cannabis markets through the creation of a new life sciences subsidiary. The Company will focus on the research and commercialization of psychedelic products in combination with its stem cell based regenerative compounds while leveraging the Company’s distribution expertise.
